Deputy Minister of Investment, Industry and Trade of the Republic of Uzbekistan, Akram Aliyev, held a meeting with the chief executive officer of Belgian biotech Allegro BIO, Lucas Decuypere, recently.
The parties discussed prospects for expanding cooperation in the fields of pharmaceuticals and biotechnology, developing high value-added innovative projects, advancing production localization, and promoting joint research and development initiatives.
Special attention was given to the company’s plans to establish production of biotechnological products in Uzbekistan, set up an R&D centre, and relocate several of its existing R&D projects to facilities in the country. The Uzbek side provided a detailed overview of available incentives for investors, opportunities within pharmaceutical free economic zones, and practical aspects of accessing export markets.
Both sides reaffirmed their commitment to actively advancing investment initiatives, developing cooperation in joint manufacturing, and expanding collaboration in scientific and research domains.
Also, last week, Allegro and US company American Regent, announced that the two companies have entered into an exclusive licensing deal for Allegro’s Synoglide, a novel treatment for osteoarthritis in the equine market.
“The partnership with leading animal health player American Regent is a clear validation of the potential of Allegro’s injectable hydrogel to treat osteoarthritis in the equine veterinary market. Horses serve as a strong translational model for humans in joint disease, an exciting prospect as we focus on human clinical development of the technology,” Decuypere said.
American Regent plans to introduce Synoglide for horses at the American Association of Equine Practitioners conference in December 2025 and expects to achieve first sales in the US in early 2026.
“We are eager to add this novel treatment for osteoarthritis to our veterinary portfolio as part of our commitment to innovative solutions that improve animal health. Synoglide offers a new approach to help veterinarians manage this challenging chronic condition that affects the lives of so many animals,” said Paul Diolosa, chief executive officer at American Regent.
Synoglide is an intra-articular injection for horses suffering from osteoarthritis and is based on Allegro’s proprietary nanotechnology platform, INTRICATE.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.